255 related articles for article (PubMed ID: 28508149)
1. Parkinson's Disease-Associated Mutant LRRK2-Mediated Inhibition of miRNA Activity is Antagonized by TRIM32.
Gonzalez-Cano L; Menzl I; Tisserand J; Nicklas S; Schwamborn JC
Mol Neurobiol; 2018 Apr; 55(4):3490-3498. PubMed ID: 28508149
[TBL] [Abstract][Full Text] [Related]
2. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression.
Gehrke S; Imai Y; Sokol N; Lu B
Nature; 2010 Jul; 466(7306):637-41. PubMed ID: 20671708
[TBL] [Abstract][Full Text] [Related]
3. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.
Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR
Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203
[TBL] [Abstract][Full Text] [Related]
4. The G2385R risk factor for Parkinson's disease enhances CHIP-dependent intracellular degradation of LRRK2.
Rudenko IN; Kaganovich A; Langston RG; Beilina A; Ndukwe K; Kumaran R; Dillman AA; Chia R; Cookson MR
Biochem J; 2017 Apr; 474(9):1547-1558. PubMed ID: 28320779
[TBL] [Abstract][Full Text] [Related]
5. P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity.
Kalogeropulou AF; Zhao J; Bolliger MF; Memou A; Narasimha S; Molitor TP; Wilson WH; Rideout HJ; Nichols RJ
Biochem J; 2018 Apr; 475(7):1271-1293. PubMed ID: 29519959
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial Calcium Dysregulation Contributes to Dendrite Degeneration Mediated by PD/LBD-Associated LRRK2 Mutants.
Verma M; Callio J; Otero PA; Sekler I; Wills ZP; Chu CT
J Neurosci; 2017 Nov; 37(46):11151-11165. PubMed ID: 29038245
[TBL] [Abstract][Full Text] [Related]
7. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.
Howlett EH; Jensen N; Belmonte F; Zafar F; Hu X; Kluss J; Schüle B; Kaufman BA; Greenamyre JT; Sanders LH
Hum Mol Genet; 2017 Nov; 26(22):4340-4351. PubMed ID: 28973664
[TBL] [Abstract][Full Text] [Related]
8. Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.
Schapansky J; Khasnavis S; DeAndrade MP; Nardozzi JD; Falkson SR; Boyd JD; Sanderson JB; Bartels T; Melrose HL; LaVoie MJ
Neurobiol Dis; 2018 Mar; 111():26-35. PubMed ID: 29246723
[TBL] [Abstract][Full Text] [Related]
9. LRRK2 Expression Is Deregulated in Fibroblasts and Neurons from Parkinson Patients with Mutations in PINK1.
Azkona G; López de Maturana R; Del Rio P; Sousa A; Vazquez N; Zubiarrain A; Jimenez-Blasco D; Bolaños JP; Morales B; Auburger G; Arbelo JM; Sánchez-Pernaute R
Mol Neurobiol; 2018 Jan; 55(1):506-516. PubMed ID: 27975167
[TBL] [Abstract][Full Text] [Related]
10. Expression of the Parkinson's Disease-Associated Gene Alpha-Synuclein is Regulated by the Neuronal Cell Fate Determinant TRIM32.
Pavlou MAS; Colombo N; Fuertes-Alvarez S; Nicklas S; Cano LG; Marín MC; Goncalves J; Schwamborn JC
Mol Neurobiol; 2017 Aug; 54(6):4257-4270. PubMed ID: 27339877
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein.
Cho HJ; Liu G; Jin SM; Parisiadou L; Xie C; Yu J; Sun L; Ma B; Ding J; Vancraenenbroeck R; Lobbestael E; Baekelandt V; Taymans JM; He P; Troncoso JC; Shen Y; Cai H
Hum Mol Genet; 2013 Feb; 22(3):608-20. PubMed ID: 23125283
[TBL] [Abstract][Full Text] [Related]
12. Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons.
López de Maturana R; Lang V; Zubiarrain A; Sousa A; Vázquez N; Gorostidi A; Águila J; López de Munain A; Rodríguez M; Sánchez-Pernaute R
J Neuroinflammation; 2016 Nov; 13(1):295. PubMed ID: 27863501
[TBL] [Abstract][Full Text] [Related]
13. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
Monfrini E; Di Fonzo A
Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
[TBL] [Abstract][Full Text] [Related]
14. GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2.
Blanca Ramírez M; Lara Ordóñez AJ; Fdez E; Madero-Pérez J; Gonnelli A; Drouyer M; Chartier-Harlin MC; Taymans JM; Bubacco L; Greggio E; Hilfiker S
Hum Mol Genet; 2017 Jul; 26(14):2747-2767. PubMed ID: 28453723
[TBL] [Abstract][Full Text] [Related]
15. LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function.
Blanca Ramírez M; Madero-Perez J; Rivero-Rios P; Martinez-Salvador M; Lara Ordonez AJ; Fernandez B; Fdez E; Hilfiker S
Curr Protein Pept Sci; 2017; 18(7):677-686. PubMed ID: 26965688
[TBL] [Abstract][Full Text] [Related]
16. Parkinson's disease-associated mutant LRRK2 phosphorylates Rab7L1 and modifies trans-Golgi morphology.
Fujimoto T; Kuwahara T; Eguchi T; Sakurai M; Komori T; Iwatsubo T
Biochem Biophys Res Commun; 2018 Jan; 495(2):1708-1715. PubMed ID: 29223392
[TBL] [Abstract][Full Text] [Related]
17. The parkinson's disease-associated LRRK2 mutation R1441G inhibits neuronal differentiation of neural stem cells.
Bahnassawy L; Nicklas S; Palm T; Menzl I; Birzele F; Gillardon F; Schwamborn JC
Stem Cells Dev; 2013 Sep; 22(18):2487-96. PubMed ID: 23600457
[TBL] [Abstract][Full Text] [Related]
18. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
[TBL] [Abstract][Full Text] [Related]
19. LRRK2 Phosphorylation: Behind the Scenes.
De Wit T; Baekelandt V; Lobbestael E
Neuroscientist; 2018 Oct; 24(5):486-500. PubMed ID: 29385885
[TBL] [Abstract][Full Text] [Related]
20. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
